ArticleBiomedicines2026
Integrative Transcriptomic Analysis Identifies COL3A1 as a Potential Tumor-Intrinsic Therapeutic Target in NSCLC.
Kaicheng Zhou, Yanyang Nan, Mengyang Li, Dongyue Hou, Caili Xu, Haiyan Yu, Jun Feng, Dianwen Ju, Ziyu Wang
Abstract read
In one paragraphArticle in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Kaicheng ZhouSchool of Pharmaceutical Sciences, Shanghai Engineering Research Center of Immunotherapeutics, Fudan University, Shanghai 201203, China.
Yanyang NanSchool of Pharmaceutical Sciences, Shanghai Engineering Research Center of Immunotherapeutics, Fudan University, Shanghai 201203, China.
Mengyang LiSchool of Pharmaceutical Sciences, Shanghai Engineering Research Center of Immunotherapeutics, Fudan University, Shanghai 201203, China.
Dongyue HouSchool of Pharmaceutical Sciences, Shanghai Engineering Research Center of Immunotherapeutics, Fudan University, Shanghai 201203, China.ORCID 0009-0001-7989-6588 Caili XuSchool of Pharmaceutical Sciences, Shanghai Engineering Research Center of Immunotherapeutics, Fudan University, Shanghai 201203, China.
Haiyan YuNovatim Immune Therapeutics (Zhejiang) Co., Ltd., Huzhou 313300, China.
Jun FengNational Key Laboratory of Lead Druggability Research, China State Institute of Pharmaceutical Industry Co., Ltd., Shanghai 201203, China.
Dianwen JuSchool of Pharmaceutical Sciences, Shanghai Engineering Research Center of Immunotherapeutics, Fudan University, Shanghai 201203, China.ORCID 0000-0002-4305-9622 Funding
AI for Science Foundation of Fudan University 0National Key Research and Development Program 2023YFC3404000National Key Research and Development Program of China 2023YFC3404000National Natural Science Foundation of China 82371781"Pioneer" & "Leading Goose" R&D Program of Zhejiang 2023C03020
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
collagen type III alpha 1epithelial–mesenchymal transitionnon-small cell lung cancerprogrammed death ligand-1single-cell transcriptomic
Identifiers
PMID42193303
PMCPMC13203928
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390